Verastem reported $17.54M in Sales Revenues for its fiscal quarter ending in December of 2025.





Sales Change Date
AbbVie USD 15B 1.62B Mar/2026
Alaunos Therapeutics USD 2K 2K Mar/2025
AstraZeneca USD 15.29B 213M Mar/2026
Curis USD 1.14M 1.41M Dec/2025
Cytokinetics USD 19.35M 1.59M Mar/2026
Gilead Sciences USD 7B 930M Mar/2026
Incyte USD 1.27B 240M Mar/2026
Laboratory Of America USD 3.54B 20M Mar/2026
Novartis USD 13.11B 226M Mar/2026
Pfizer USD 14.5B 3.08B Mar/2026
Roche Holding CHF 15.65B 274.5M Dec/2025
TG Therapeutics USD 194.8M 2.23M Mar/2026
Verastem USD 17.54M 7.53M Dec/2025